ClinicalTrials.gg
RecruitingNCT07203053START-lungUpdated Nov 19, 2026

A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2

A Phase 2 interventional study of Tarlatamab in Extensive Stage Lung Small Cell Cancer, sponsored by ETOP IBCSG Partners Foundation. Recruiting at 13 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by ETOP IBCSG Partners Foundation · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 19, 2026Site recruiting status changed6 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

START-lung is an international, multicentre, single-arm phase II trial. Protocol treatment consists of tarlatamab administered as an intravenous infusion until disease progression according to RECIST v1.1 criteria, unacceptable toxicity, or patient decision, whichever comes first. The primary objective of the trial is to assess the clinical efficacy of tarlatamab, in terms of 12-month OS rate, in patients with ES-SCLC and ECOG PS 2 who have previously received only one line of platinum-etoposide doublet chemotherapy with immune-checkpoint inhibition and whose disease has progressed.

02

Conditions studied

  • Extensive Stage Lung Small Cell Cancer

Keywords

  • ES-SCLC
  • Tarlatamab
03

In context

Lead sponsor

ETOP IBCSG Partners Foundation is the lead sponsor of 52 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed ES-SCLC.
  • Previous treatment with only one line of platinum-etoposide doublet chemotherapy with immune-checkpoint inhibition for SCLC.

Patients treated with a platinum-etoposide doublet chemotherapy for prior limited stage (LS)-SCLC may be eligible for the study if the disease has progressed on treatment or within 6 months from chemotherapy completion (i.e. during durvalumab consolidation): the platinum-etoposide will count as one prior line of therapy.

  • Progressive disease on or after the first-line treatment for SCLC.
  • Performance Status 2.
  • Age ≥18 years.
  • Adequate haematological, renal and liver function.
  • Coagulation function: (PT)/international normalised ratio (INR) and partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) ≤1.5x , except for patients receiving anticoagulation, who must be on a stable dose of anticoagulation therapy for 6 weeks prior to enrolment.
  • Pulmonary function:

    • No pleural effusion. Pleural effusion managed with indwelling pleural catheter (e.g., PleurX) are allowed.
    • Baseline oxygen saturation >90% on room air.
  • Cardiac function: (LVEF) ≥50%, no clinically significant pericardial effusion as determined by an echocardiogram (ECHO) or multigated acquisition (MUGA) scan (preferred), and no clinically significant (ECG) findings.
  • Women of , must have a negative urinary or serum pregnancy test within 5 weeks before enrolment. Pregnancy test must be repeated within 3 days before the first dose of tarlatamab treatment.
  • Written must be signed and dated by the patient and the investigator prior to any trial-related intervention.

Exclusion criteria

Exclusion Criteria:

  • Symptomatic Patients with untreated asymptomatic brain metastases and patients with treated and stable brain metastases are eligible.
  • Diagnosis or evidence of or spinal cord compression
  • Prior history of immune- treatment resulting in:

    • any severe or life-threatening immune-mediated adverse event,
    • history of immune-mediated encephalitis or another immune-mediated CNS event (any grade),
    • grade ≥2 immune-mediated recurrent pneumonitis,
    • infusion-related reactions leading to permanent discontinuation of the immunotherapy agent.

Exception: patients with a history of immune-checkpoint inhibitor-induced endocrinopathy which is clinically stable on replacement therapy.

  • Active disease that has required systemic treatment (except replacement therapy) within the past 2 years or any other diseases requiring therapy while on study.
  • History of solid organ transplantation.
  • Treatment with live virus, including within 14 days prior to enrolment and inactive vaccines (e.g., non-live or non-replicating agent) and live viral non-replicating vaccines (e.g., Jynneos for Monkeypox infection) within 3 days prior to enrolment.
  • History of other within the past 2 years, with the following exceptions:

    • Low-risk malignancy treated with curative intent and with no known active disease present for ≥1 year before enrolment and believed to be at low risk for recurrence per investigator discretion.
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
    • Adequately treated cervical carcinoma in situ without evidence of disease.
    • Adequately treated breast ductal carcinoma in situ without evidence of disease.
    • Prostatic intraepithelial neoplasia without evidence of prostate cancer.
    • Adequately treated urothelial papillary non-invasive carcinoma or carcinoma in situ.
  • Myocardial infarction and/or symptomatic congestive heart failure ( >class II) within 12 months prior to enrolment.
  • History of arterial thrombosis (e.g., stroke or ) within 12 months prior to enrolment.
  • Presence/history of an uncontrolled viral infection:

    • Known uncontrolled (HIV) infection.
    • Active infection (patients with detectable hepatitis C antibody [HCV Ab] and HCV RNA viral load above the limit of quantification).
    • Patients with presence of HCV Antibodies and HCV RNA viral load below the limit of quantification (HCV RNA negative) with or without prior treatment are allowed.
    • Active infection (presence of hepatitis B surface antigen [HBsAg] and hepatitis B virus [HBV] DNA viral load above the limit of quantification [HBV DNA positive]).
    • Patients with resolved HBV infection defined as absence of HBsAg and presence of HBV core antibody (anti-HBc) followed by an HBV DNA viral load below the limit of quantification (HBV DNA negative) are allowed, with a requirement for regular monitoring for reactivation for the duration of treatment on the study and assessing the need for HBV prophylaxis therapy per local or institutional guidelines.
    • Patients with chronic HBV infection inactive carrier state defined as presence of HBsAg and HBV DNA viral load below the limit of quantification [HBV DNA negative] are allowed, with a requirement for regular monitoring for reactivation for the duration of treatment on the study and assessing the need for HBV prophylaxis therapy per local or institutional guidelines.
  • Receiving systemic therapy or any other form of immunosuppressive therapy within 7 days prior to first dose of study treatment.

    • Prophylactic dexamethasone for the management of tarlatamab-related adverse events and any anti-emetic therapies are allowed.
    • Low-dose corticosteroids (prednisone ≤10 mg per day or equivalent) is permitted during the trial.
  • Patients with symptoms and/or clinical signs and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection within 7 days prior to the first dose of study treatment.

    • Patient has known active infection requiring parenteral antibiotic treatment. Upon completion of parenteral antibiotics and resolution of symptoms, the patient may be considered eligible for the study from an infection standpoint.
    • Note: Simple urinary tract infection (UTI) and uncomplicated bacterial pharyngitis are permitted if responding to active treatment. Subjects requiring oral antibiotics who have been afebrile for >24 hours, have no leucocytosis, nor clinical signs of infection are eligible. Screening for chronic infectious conditions is not required unless otherwise noted as exclusion criteria.
  • Evidence of interstitial lung disease or active, non-infectious pneumonitis.
  • Major surgical procedures within 5 weeks prior to enrolment.
  • Any concurrent medical condition which, in the opinion of the investigator, would compromise patient safety or interfere with the evaluations for tarlatamab.
  • Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
  • Women who are pregnant or in the period of lactation.
  • Sexually active men and women of who are not willing to use an effective method during the trial until at least 60 days after the last dose of tarlatamab treatment.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Tarlatamab

    Drug: Tarlatamab

Interventions

  • DrugAMG 757Studies of AMG 757AMG 757 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Protocol treatment consists of tarlatamab, administered as an intravenous (i.v.) infusion: * 1 mg on day 1 (C1D1), * 10 mg on day 8 (C1D8) and * 10 mg on day 15 (C1D15), * then 10 mg every two weeks (Q2W) until disease progression according to RECIST v1.1 criteria, unacceptable toxicity, or patient decision, whichever comes first.

06

What researchers measure

Primary outcomes

  1. Overall survival rate at 12 months (12-month OS)

    The OS rate at 12 months is the primary endpoint of the trial. It is defined as the proportion of patients who are alive at 12 months from enrolment. The rate will be calculated as the number of patients alive at 12 months divided by the number of patients on follow-up at 12 months or with an earlier observed death event.

    Time frame: OS is defined as the time from the date of enrolment until death from any cause. Assessed for approximately up to 41 months.

Secondary outcomes

  1. Objective response rate (ORR)

    Objective response rate (ORR) is defined as the rate of patients, among all those enrolled, who achieve a best overall response \[complete response (CR) or partial response (PR)\] according to the RECIST v1.1 across all post-enrolment time-points until the end of follow up for disease progression.

    Time frame: Assessed for approximately up to 41 months.

  2. Duration of response (DoR)

    Duration of response (DoR) is defined as the time from the date of first documentation of objective response (CR or PR according to RECIST v1.1) to the date of first documented progression or death. Censoring will occur at the last tumour assessment with response other than progression. Patients without tumour assessment after documented objective response will be censored at the date of documented objective response (plus 1 day).

    Time frame: Assessed for approximately up to 41 months.

  3. Disease control rate (DCR)

    Disease control rate (DCR) is defined as the rate of patients, among all those enrolled, who achieve CR or PR according to RECIST v1.1 or stabilisation of disease (SD), lasting for at least 12 weeks.

    Time frame: Assessed for approximately up to 41 months.

  4. Progression-free survival (PFS)

    Progression-free survival (PFS) is defined as the time from the date of enrolment until documented progression (according to RECIST v1.1) or death if progression is not documented. Censoring (for patients without documented progression or death) will occur at the date of last tumour assessment. Patients without a post-baseline tumour assessment will be censored at the date of enrolment (plus 1 day).

    Time frame: Assessed for approximately up to 41 months.

  5. Incidence, nature, and severity of adverse events

    Incidence, nature, and severity of adverse events according to CTCAE v5, except for CRS and ICANS, that are graded according to the ASTCT criteria21 and TLS that are graded according to the Cairo-Bishop classification All safety parameters will be summarised in tables to evaluate the toxicity/safety profile of the protocol treatment based on: * Adverse events (AEs) according to CTCAE v5.0 (any-cause as well as treatment-related) including AEs leading to dose delays and/or interruptions, withdrawal of protocol treatment, and death. * Occurrence of CRS and ICANS, defined according to the American Society for Transplantation and Cellular Therapy (ASTCT) criteria published by Lee et al. (2019). * Occurrence of TLS, defined according to the Cairo-Bishop classification.22 * Severe and serious AEs. * Laboratory parameters and abnormalities, and vital signs.

    Time frame: Assessed for approximately up to 41 months.

07

Study locations

13 of 13 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Oct 2029, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Oct 2, 2025
StartActual
Apr 15, 2026
Primary completionEst.
Oct 2029
CompletionEst.
Oct 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites removed. 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Irccs Irst · Meldola, ItalyNot yet recruiting→Recruiting
  • Santa Maria della Misericordia Hospital · Perugia, ItalyNot yet recruiting→Recruiting
Show 6 removed
  • Institut Bergonie · Bordeaux, France
  • Hôpital Nord de Marseille · Marseille, France
  • Instituto Europeo di Oncologia (IEO) · Milan, Italy
  • AO San Giovanni Addolorata · Roma, Italy
  • ICO Hospitalet H. Duran I Reynals / H. Bellvitge · Barcelona, Spain
  • Hospital Universitatrio Puerta del Hierro · Madrid, Spain
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    6 sites removed. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Irccs Irst · Meldola, ItalyNot yet recruiting→Recruiting
    • Santa Maria della Misericordia Hospital · Perugia, ItalyNot yet recruiting→Recruiting
    Show 6 removed
    • Institut Bergonie · Bordeaux, France
    • Hôpital Nord de Marseille · Marseille, France
    • Instituto Europeo di Oncologia (IEO) · Milan, Italy
    • AO San Giovanni Addolorata · Roma, Italy
    • ICO Hospitalet H. Duran I Reynals / H. Bellvitge · Barcelona, Spain
    • Hospital Universitatrio Puerta del Hierro · Madrid, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07203053
Lead sponsor
ETOP IBCSG Partners Foundation
Collaborators
Amgen
Responsible party
Sponsor
First posted
Oct 2, 2025
Start date
Apr 15, 2026
Primary completion
Oct 2029 (estimated)
Completion
Oct 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

Heidi Roschitzki, PhD
Contact
heidi.roschitzki@etop.ibcsg.org
+41 31 511 94 00
Susanne Roux
Contact
START-lung@etop.ibcsg.org
+41 31 511 94 00
Maurice Pérol, MD
study chair · Centre Léon Bérard, Lyon, France
Federico Capuzzo, MD
study chair · IRCCS Regina Elena, Rome, Italy

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AMG 757

Start the discussion